A preliminary investigation of tobacco co-use on endocannabinoid activity in people with cannabis use
- PMID: 40799255
- PMCID: PMC12341708
- DOI: 10.1016/j.dadr.2025.100369
A preliminary investigation of tobacco co-use on endocannabinoid activity in people with cannabis use
Abstract
Tobacco is commonly co-used with cannabis. This is unfortunate because tobacco co-use exacerbates select clinical consequences associated with cannabis use. Evidence demonstrates that low levels of anandamide, a prominent endocannabinoid, correlate with worse clinical outcomes. Fatty acid amide hydrolase (FAAH) degrades anandamide, and greater FAAH levels may underlie poorer clinical outcomes in people who co-use relative to those who use only cannabis. Therefore, we tested whether tobacco co-use increases FAAH levels beyond those associated with cannabis use alone. Cannabis-using participants (N = 13) were parsed into individuals with daily tobacco use (CT, n = 5) and no current tobacco use (CAN, n = 8). We evaluated group differences in FAAH, quantified using positron emission tomography and [11C]CURB, while controlling for sex and FAAH genotype in the prefrontal cortex, hippocampus, thalamus, sensorimotor striatum, substantia nigra, and cerebellum. A significant group x ROI interaction for [11C]CURB λk3 [F(5, 45)= 3.15, p = 0.016] emerged. Bonferroni-corrected post-hoc tests indicated greater FAAH levels in CT compared to CAN in the substantia nigra (p = 0.023, d=1.54) and cerebellum (p = 0.003, d=1.76), while a trend emerged in the sensorimotor striatum (p = 0.054, d=1.33). Preliminary findings suggest that tobacco co-use is associated with elevated FAAH activity relative to cannabis-only use, which may underlie poorer clinical outcomes associated with co-use.
Keywords: Anandamide; Cannabis; Co-use; Endocannabinoid; Fatty acid amide hydrolase; Tobacco.
© 2025 The Author(s).
Conflict of interest statement
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Figures


Similar articles
-
Prescription of Controlled Substances: Benefits and Risks.2025 Jul 6. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. 2025 Jul 6. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. PMID: 30726003 Free Books & Documents.
-
A multi-site study examining the tobacco withdrawal trajectory in people with tobacco and cannabis co-use.Drug Alcohol Depend. 2025 Sep 1;274:112778. doi: 10.1016/j.drugalcdep.2025.112778. Epub 2025 Jul 3. Drug Alcohol Depend. 2025. PMID: 40633181 Clinical Trial.
-
Cannabis and schizophrenia.Cochrane Database Syst Rev. 2014 Oct 14;2014(10):CD004837. doi: 10.1002/14651858.CD004837.pub3. Cochrane Database Syst Rev. 2014. PMID: 25314586 Free PMC article.
-
Interventions to reduce harm from continued tobacco use.Cochrane Database Syst Rev. 2016 Oct 13;10(10):CD005231. doi: 10.1002/14651858.CD005231.pub3. Cochrane Database Syst Rev. 2016. PMID: 27734465 Free PMC article.
-
Interventions for tobacco use cessation in people living with HIV.Cochrane Database Syst Rev. 2024 Aug 5;8(8):CD011120. doi: 10.1002/14651858.CD011120.pub3. Cochrane Database Syst Rev. 2024. PMID: 39101506 Free PMC article.
References
-
- Adermark L. Modulation of endocannabinoid-mediated long-lasting disinhibition of striatal output by cholinergic interneurons. Neuropharmacology. 2011;61(8):1314–1320. - PubMed
-
- American Psychiatric Association, 2000. Diagnostic and statistical manual of mental disorders (Revised 4th ed.). Author, Washington, DC.
-
- Baggio S., Deline S., Studer J., Mohler-Kuo M., Daeppen J.B., Gmel G. Routes of administration of cannabis used for nonmedical purposes and associations with patterns of drug use. J. Adolesc. Health. 2014;54(2):235–240. - PubMed
LinkOut - more resources
Full Text Sources
Miscellaneous